Medical device development company Evolve Medtech Partners announced on Wednesday that Rob Abrams has joined the company's team.
With more than 30 years of experience in biomedical device product development, research, operational management, new business development and strategic investments, Abrams currently serves as a senior global business development and strategy executive with Kaneka Corp.
Abrams previously served as an operating partner at Sanderling Ventures and CEO of Pulsar Vascular, which was acquired by Johnson & Johnson.
Before he joined Sanderling, Abrams was group vice president of new business development for cardiovascular at Boston Scientific and has also served in various roles at Target Therapeutics, Localmed, Howmedica, and Guidant. lve-medtech.com
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA